News >

Novel Strategies Explored to Optimize Osimertinib Treatment and Beyond in EGFR+ NSCLC

Brandon Scalea
Published: Tuesday, Jun 25, 2019

Mark G. Kris, MD

Mark G. Kris, MD
The emergence of osimertinib (Tagrisso) in the EGFR-positive non–small cell lung cancer (NSCLC) treatment paradigm has led to unprecedented progression-free survival (PFS) in patients, said Mark G. Kris, MD. Now, researchers are channeling their efforts into optimizing patient selection for and outcomes with the targeted therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication